Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera
We report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization responses. HK.3-JN.1 RBD-heterodimer induced balanced and potent neutralizing responses against recently-circulating SARS-CoV-2 sub-variants in mice, supporting to replace the COVID-19 antigen containing JN.1 or its sub-variants.
Authors
- George F. Gao (ORCID: https://orcid.org/0000-0002-3869-615X)
- Yaling An
- Minrun Duan
- Dedong Li (ORCID: https://orcid.org/0000-0002-9474-390X)
- Kun Xu (ORCID: https://orcid.org/0000-0002-9762-5001)
- Lianpan Dai (ORCID: https://orcid.org/0000-0001-8352-1327)
- Haitang Xie
- Xueyuan Liu (ORCID: https://orcid.org/0000-0002-3869-8809)
- Xin Zhao (ORCID: https://orcid.org/0000-0002-2001-1343)
- Ting Yang (ORCID: https://orcid.org/0000-0001-6604-8937)
- Yuanzhuo Wang (ORCID: https://orcid.org/0000-0002-1940-9741)
Institutions
- Wannan Medical College (CN)
- Shandong University (CN)
- Chinese Academy of Sciences (CN)
- Computer Network Information Center (CN)
- Institutes of Science and Development (CN)
- Institute of Microbiology (CN)
- First Affiliated Hospital of Wannan Medical College (CN)
Publication Details
- Journal
- npj Vaccines
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1038/s41541-024-01016-6
- Citations
- 18
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 7.00
Funders
- Bill and Melinda Gates Foundation
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation